280 related articles for article (PubMed ID: 11982720)
1. Management of patients with chronic hepatitis B.
Liaw YF
J Gastroenterol Hepatol; 2002 Apr; 17(4):406-8. PubMed ID: 11982720
[TBL] [Abstract][Full Text] [Related]
2. Treatment of chronic hepatitis B: case selection and duration of therapy.
Leung N
J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
[TBL] [Abstract][Full Text] [Related]
3. Management of viral hepatitis B.
Pramoolsinsup C
J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S125-45. PubMed ID: 12000599
[TBL] [Abstract][Full Text] [Related]
4. Therapy of chronic hepatitis B: current challenges and opportunities.
Liaw YF
J Viral Hepat; 2002 Nov; 9(6):393-9. PubMed ID: 12431200
[TBL] [Abstract][Full Text] [Related]
5. Clinical potential of emerging new agents in hepatitis B.
Farrell GC
Drugs; 2000 Oct; 60(4):701-10. PubMed ID: 11085196
[TBL] [Abstract][Full Text] [Related]
6. Chronic hepatitis B--treatment with nucleoside analogues.
Leung N
Med J Malaysia; 2005 Jul; 60 Suppl B():22-7. PubMed ID: 16108169
[TBL] [Abstract][Full Text] [Related]
7. Current therapy with nucleoside/nucleotide analogs for patients with chronic hepatitis B.
Xu XW; Chen YG
Hepatobiliary Pancreat Dis Int; 2006 Aug; 5(3):350-9. PubMed ID: 16911930
[TBL] [Abstract][Full Text] [Related]
8. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
Maklad S; Doss W; El Din SS; Hassan K; Zeid AA
Arab J Gastroenterol; 2014 Mar; 15(1):1-5. PubMed ID: 24630505
[TBL] [Abstract][Full Text] [Related]
9. [A study on the treatment of chronic hepatitis B with YMDD mutation].
Qiu YW; Jiang XH; Huang LH; Hu TH; Ding H; Jiang YM; Dai YX; Zhou M
Zhonghua Gan Zang Bing Za Zhi; 2009 Mar; 17(3):171-4. PubMed ID: 19335977
[TBL] [Abstract][Full Text] [Related]
10. Short-term lamivudine therapy in patients with chronic hepatitis B.
Chien RN; Liaw YF
Intervirology; 2003; 46(6):362-6. PubMed ID: 14688453
[TBL] [Abstract][Full Text] [Related]
11. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy.
Leung NW; Lai CL; Chang TT; Guan R; Lee CM; Ng KY; Lim SG; Wu PC; Dent JC; Edmundson S; Condreay LD; Chien RN;
Hepatology; 2001 Jun; 33(6):1527-32. PubMed ID: 11391543
[TBL] [Abstract][Full Text] [Related]
12. Beneficial effects of 'lamivudine pulse' therapy in HBeAg-positive patients with normal ALT*.
Sarin SK; Sandhu BS; Sharma BC; Jain M; Singh J; Malhotra V
J Viral Hepat; 2004 Nov; 11(6):552-8. PubMed ID: 15500556
[TBL] [Abstract][Full Text] [Related]
13. Treatment of patients with chronic hepatitis B with adefovir dipivoxil.
Tong MJ; Tu SS
Semin Liver Dis; 2004; 24 Suppl 1():37-44. PubMed ID: 15192800
[TBL] [Abstract][Full Text] [Related]
14. Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B.
Lee JM; Park JY; Kim DY; Nguyen T; Hong SP; Kim SO; Chon CY; Han KH; Ahn SH
Antivir Ther; 2010; 15(2):235-41. PubMed ID: 20386079
[TBL] [Abstract][Full Text] [Related]
15. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.
Dienstag JL; Schiff ER; Mitchell M; Casey DE; Gitlin N; Lissoos T; Gelb LD; Condreay L; Crowther L; Rubin M; Brown N
Hepatology; 1999 Oct; 30(4):1082-7. PubMed ID: 10498663
[TBL] [Abstract][Full Text] [Related]
16. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B.
Peters MG; Hann Hw Hw; Martin P; Heathcote EJ; Buggisch P; Rubin R; Bourliere M; Kowdley K; Trepo C; Gray Df Df; Sullivan M; Kleber K; Ebrahimi R; Xiong S; Brosgart CL
Gastroenterology; 2004 Jan; 126(1):91-101. PubMed ID: 14699491
[TBL] [Abstract][Full Text] [Related]
17. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
[TBL] [Abstract][Full Text] [Related]
18. Management of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B.
Liaw YF
J Gastroenterol Hepatol; 2002 Dec; 17 Suppl 3():S333-7. PubMed ID: 12472959
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of lamivudine in HBeAg-negative chronic hepatitis B.
Rizzetto M
J Med Virol; 2002 Apr; 66(4):435-51. PubMed ID: 11857520
[TBL] [Abstract][Full Text] [Related]
20. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase.
van Nunen AB; Hansen BE; Suh DJ; Löhr HF; Chemello L; Fontaine H; Heathcote J; Song BC; Janssen HL; de Man RA; Schalm SW
Gut; 2003 Mar; 52(3):420-4. PubMed ID: 12584227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
